ArticleEULAR rheumatology open2025

Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study.

Tomoko Hasunuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.